EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Levothyroxine Treatment During Pregnancy: A Metabolomics Study

Olli Kärkkäinen iD, Heidi Sahlman iD, Leea Keski-Nisula iD, Jaana Rysä iD

Basic & Clinical Pharmacology & Toxicology · 2026-07 · 139 (1)

DOI: 10.1111/bcpt.70246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 22.05.2026. Verfasst von Olli Kärkkäinen und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Thyroxine, Fetal Blood, Pregnancy Complications, Hypothyroidism. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Horizon 2020 Framework Programme, Avohoidon Tutkimussäätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Levothyroxine is one of the most prescribed drugs during pregnancy. Our aim was to determine levothyroxine treatment‐associated changes in the metabolite profiles and link these to the health of the newborn. Metabolite profiles of 118 levothyroxine‐treated and 118 healthy control pregnancies were determined with nuclear magnetic resonance‐based metabolomics from (1) umbilical cord blood samples, (2) samples collected during the first trimester and (3) during delivery from the pregnant women. There was a modest negative correlation between cord blood thyroid stimulating hormone (CBTSH) concentrations and Apgar scores at the 1 and 5 min time points in levothyroxine‐treated pregnancies. Furthermore, the concentrations of cord serum metabolites linked with anaerobic glycolysis, for example, lactate, citrate and glycerol, as well as all measured amino acids were negatively associated with Apgar scores. Moreover, cord serum concentrations of lactate, glycerol and alanine were modestly correlated with CBTSH concentrations in the levothyroxine‐treated pregnancies. In the during delivery samples, there was small but significant decrease in cholesteryl esters, cholesterol and phospholipids in small very low‐density lipoprotein in the levothyroxine‐treated pregnancies. In conclusion, levothyroxine treatment during pregnancy was associated with relatively small alterations in the blood metabolite profiles during pregnancy and labour.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThyroxineFetal BloodPregnancy ComplicationsHypothyroidismHumansFemalePregnancyMetabolomicsAdultThyrotropinInfant, NewbornMagnetic Resonance SpectroscopyCase-Control StudiesPregnancy Trimester, First

Stichwörter der Autor:innen

NMRhypothyroidismlevothyroxinemetabolomicspregnancy

Substanzen

ThyroxineThyrotropin

Autor:innen und Institutionen

  • School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
  • Institute of Clinical Medicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.
  • Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland.

ORCID-Profile: Olli Kärkkäinen, Heidi Sahlman, Leea Keski-Nisula, Jaana Rysä

Förderung

  • Horizon 2020 Framework Programme
  • Avohoidon Tutkimussäätiö

Zitieren

APA

Kärkkäinen, O., Sahlman, H., Keski-Nisula, L., & Rysä, J. (2026). Levothyroxine Treatment During Pregnancy: A Metabolomics Study. Basic & Clinical Pharmacology & Toxicology, 139(1). https://doi.org/10.1111/bcpt.70246

Vancouver

Kärkkäinen O, Sahlman H, Keski-Nisula L, Rysä J. Levothyroxine Treatment During Pregnancy: A Metabolomics Study. Basic & Clinical Pharmacology & Toxicology. 2026;139(1). doi:10.1111/bcpt.70246

BibTeX
@article{Krkkinen2026,
  author = {Kärkkäinen, Olli and Sahlman, Heidi and Keski-Nisula, Leea and Rysä, Jaana},
  title = {Levothyroxine Treatment During Pregnancy: A Metabolomics Study},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  volume = {139},
  number = {1},
  doi = {10.1111/bcpt.70246}
}
Kostenlos starten →